Ipsen News | finanzen.ch

Ipsen Aktie VALOR 2348805 / ISIN FR0010259150

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

21.05.25	Ipsen S.A. - Annual General Meeting held on 21 May 2025 (GlobeNewswire)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22	Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22	Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)
14.04.17	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)
07.02.13	Eziclen® / Izinova® a New Product for Bowel Cleansing Successfully Completed European Decentralised Registration Procedure (Businesswire)
17.01.13	Teijin Pharma to Launch Ipsen's Somatuline® Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan (Businesswire)
07.01.13	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
07.01.13	Ipsen S.A. : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.01.13	Ipsen's Corporate Agenda for 2013 (Businesswire)
18.12.12	Oncodesign And the Laboratory for Neurobiology and Gene Therapy at The KU Leuven Enter into a Research Collaboration for Advancing Drug Discovery Efforts with Ipsen in Parkinson's Disease (Businesswire)
10.12.12	Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer (Businesswire)
06.12.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
03.12.12	Ipsen and Galderma increase their collaboration for Dysport® in new territories (Businesswire)
20.11.12	Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A (Businesswire)
09.11.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
31.10.12	Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection (Businesswire)
29.10.12	Ipsen’s third quarter and first nine months 2012 sales (Businesswire)
23.10.12	Ipsen US Awards up to $300,000 for Dystonia Fellowship Grants in 2013 (Businesswire)
19.10.12	Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications (Businesswire)
05.10.12	IPSEN SA: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.10.12	Ipsen initiates a phase II "Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod (Businesswire)
03.10.12	Ipsen Provides Update on Recent Agreement with Inspiration (Businesswire)
01.10.12	Tasquinimod Biomarker Phase II data presented at ESMO 2012 (Businesswire)
10.09.12	Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US (Businesswire)
07.09.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
28.08.12	Ipsen's Half-Year 2012 Results (Businesswire)
21.08.12	Ipsen and Inspiration Biopharmaceuticals Renegotiate Strategic Partnership Agreement (Businesswire)
02.08.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
11.07.12	Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope (Businesswire)
10.07.12	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
10.07.12	Ipsen’s Partner Inspiration Biopharmaceuticals Announces Hold of Phase III Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Hemophilia B (Businesswire)
06.07.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
29.06.12	Ipsen’s Somatuline® Receives Marketing Approval in Japan for the Treatment of Acromegaly and Pituitary Gigantism (Businesswire)
05.06.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
04.06.12	Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer (Businesswire)
01.06.12	Combined Shareholders’ Meeting of IPSEN S.A. Held on 1 June 2012 (Businesswire)
21.05.12	600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	608.20	0.33 %	K V
Swisscom	565.50	-0.26 %	K V
Roche Hldg G	260.20	-0.27 %	K V
Part Grp Hldg	1’093.50	-0.36 %	K V
Zurich Insur Gr	576.60	-0.93 %	K V
Swiss Life Hldg	816.20	-1.52 %	K V
Swiss Re	145.55	-1.85 %	K V
Alcon	70.56	-1.95 %	K V
Sonova Hldg	257.70	-2.05 %	K V
CieFinRichemont	155.90	-2.38 %	K V